Analysis of real‐world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma
Mosunmoluwa Oyenuga, Subir Goyal, Lindsay M. Hannan, Oluwadunni Emiloju, Gideon T. Dosunmu, Ruoyu Miao, Olumide Gbolahan, Maria Russell, Jolinta Lin, Jeffrey M. Switchenko, Olatunji B. AleseAbstract
Background
Nonmetastatic esophagogastric adenocarcinoma require multimodal treatment for management. However, real‐world treatment patterns and outcomes in these patients are limited. We evaluated the survival outcomes associated with the common treatment combinations in the National Cancer Database.
Methods
A total of 4715 patients met the predefined inclusion and exclusion criteria. Four groups were created: group 1, preoperative chemotherapy; group 2, perioperative chemotherapy; group 3, preoperative chemotherapy followed by chemoradiation; and group 4, preoperative chemoradiotherapy. Kaplan–Meier curves were used to assess overall survival. Cox proportional hazard regression estimated hazard ratios (HR) and 95% CIs for associations between covariates and overall survival. Inverse probability of treatment weighting based on propensity scores were used to account for differences in baseline characteristics between treatment groups.
Results
The median age was 63 years; 75.9% were male and 82.9% were non‐Hispanic White; overall, 47.5% had clinical stage III disease and 57.8% had regional lymph node involvement. Median follow‐up was 79.5 months. Patients who received perioperative chemotherapy had improved median overall survival compared with patients who received preoperative chemoradiotherapy (79.1 vs 74.6 months; p < .001). After adjustment for age, race, Charlson–Deyo Score, facility type, year of diagnosis, presence of regional lymph nodes, clinical stage, the association remained statistically significant (HR = 0.78; 95% CI, 0.66–0.92; p = .003).
Conclusion
Although several multimodality treatment strategies are used for esophagogastric adenocarcinoma, perioperative chemotherapy is associated with better overall survival compared to preoperative chemoradiotherapy.